龚艳君,霍勇

• 1:北京大学第一医院心内科

摘要(Abstract)：

<正>1977年瑞士籍的德国裔医师Gruentzig~([1])完成世界首例经皮冠状动脉腔内成形术，从此开创了介入心脏病学的新纪元。随着时间推移，冠心病、先天性心脏病、心律失常、心脏瓣膜病的介入诊疗技术得到巨大发展，介入心脏病学已成为心脏病学的重要分支学科，介入诊疗操作也日渐成为心血管医师的重要日常工作。近10多年来，心血管介入技术不断向新领域拓展，尤其是高血压领域。高血压是多种心血管疾病的危险因素，是世界性的慢性非传染性疾病，是全球疾病负担的首要病因。我国是高血压大国，2018年中国慢性病与危险因素监测显示中国18岁及以上成人高血压患病率为27.5%~([2])，所以高血压是中国面临的重要公共卫生问题。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 龚艳君,霍勇

参考文献(References)：

• [1] Gruentzig AR. Percutaneous transluminal coronary angioplasty[J]. Semin Roentgenol,1981,16(2):152-153. DOI:10.1016/0037-198x(81)90049-3.
• [2]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022, 30(7):481-496. DOI:10.3969/j.issn.1004-8812.2022.07.001.
• [3]王捷. 2021年欧洲高血压学会关于经导管去肾交感神经术立场文件的解读：经导管去肾交感神经术真的要来了![J].中国介入心脏病学杂志，2021,29(10):554-557. DOI:10.3969/j.issn.1004-8812.2021.10.003.
• [4] Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months[J]. Hypertension,2011,57(5):911-917. DOI:10.1161/HYPERTENSIONAHA.110.163014.
• [5] Symplicity HTN-2 Investigators,Esler MD, Krum H,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.DOI:10.1016/S0140-6736(10)62039-9.
• [6] Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401. DOI:10.1056/NEJMoa1402670.
• [7] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension:the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J].J Hypertens,2018,36(10):1953-2041. DOI:10.1097/HJH.0000000000001940.
• [8] Kandzari DE, B?hm M, Mahfoud F, et al. Ef fect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month e ffi cacy and safety results from the SPYRAL HTNON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355. DOI:10.1016/S0140-6736(18)30951-6.
• [9] Azizi M, Sanghvi K, Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill(RADIANCEHTN TRIO):a randomised, multicentre, single-blind, shamcontrolled trial[J]. Lancet,2021,397(10293):2476-2486.DOI:10.1016/S0140-6736(21)00788-1.
• [10] B?hm M,Kario K,Kandzari DE,et al. E ffi cacy of catheter-based renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised, sham-controlled trial[J]. Lancet,2020,395(10234):1444-1451. DOI:10.1016/S0140-6736(20)30554-7.
• [11] Townsend RR, Mahfoud F, Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED):a randomised, sham-controlled, proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170. DOI:10.1016/S0140-6736(17)32281-X.
• [12] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension(RADIANCE-HTN SOLO):a multicentre, international, single-blind, randomised, shamcontrolled trial[J]. Lancet,2018,391(10137):2335-2345.DOI:10.1016/S0140-6736(18)31082-1.
• [13] Schmieder RE,Mahfoud F,Mancia G,et al. European Society of Hypertension position paper on renal denervation 2021[J].J Hypertens,2021,39(9):1733-1741. DOI:10.1097/HJH.0000000000002933.
• [14] Mahfoud F, Kandzari DE, Kario K,et al. Long-term e ffi cacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED):a randomised, sham-controlled trial[J]. Lancet,2022,399(10333):1401-1410. DOI:10.1016/S0140-6736(22)00455-X.
• [15] Sarathy H, Salman LA. Can renal denervation replace medications for patients with hypertension?[J]. Lancet,2022,399(10333):1363-1365. DOI:10.1016/S0140-6736(22)00614-6.
• [16] Bhatt DL,Vaduganathan M,Kandzari DE,et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension：fi nal follow-up of the randomised SYMPLICITY HTN-3 Trial[J]. Lancet, 2022,400(10361):1405-1416.DOI:10.1016/S0140-6736(22)01787-1.
• [17] Mahfoud F,Mancia G,Schmieder RE,et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range[J]. J Am Coll Cardiol,2022,80(20):1871-1880. DOI:10.1016/j.jacc.2022.08.802.
• [18] Azizi M,Mahfoud F,Weber MA,et al. Effects of renal denervation vs. sham in resistant hypertension after medication escalation:prespecified analysis at 6 months of the RADIANCEHTN TRIO randomized clinical trial[J]. JAMA Cardiol,2022,7(12):1244-1252. DOI:10.1001/jamacardio.2022.3904.
• [19] Ji M,Chen H,Shen L,et al. Validation of a novel renal denervation system with cryoablation:a preclinical study and case series[J].JACC Basic Transl Sci,2022,7(2):101-112. DOI:10.1016/j.jacbts.2021.11.002.
• [20] Li P,Liu B,Wu X,et al. Perirenal adipose af ferent nerves sustain pathological high blood pressure in rats[J]. Nat Commun,2022,13(1):3130. DOI:10.1038/s41467-022-30868-6.